Jacobio Pharmaceuticals Group Co., Ltd. (stock code 01167) reported a share buy-back executed on 22 June 2026.

The company repurchased 111,600 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 4.41 and HKD 4.51, for a volume-weighted average cost of about HKD 4.47 per share. Total consideration amounted to HKD 0.50 million.

Following the transaction, the number of issued shares (excluding treasury shares) fell by 0.014% from 783.31 million to 783.19 million. Treasury shares increased to 8.56 million, while the total issued share capital remained unchanged at 791.76 million.

The repurchase forms part of a mandate granted on 5 June 2026 permitting the company to buy back up to 78.37 million shares. Cumulative repurchases under this authority now stand at 530,700 shares, representing 0.07% of the company’s issued shares on the mandate date. All repurchased shares are currently held in treasury; none have been cancelled.

In line with Hong Kong listing rules, Jacobio Pharmaceuticals is subject to a moratorium on issuing new shares or disposing of treasury shares until 22 July 2026.